U.S. approves new booster of COVID-19 vaccines, “mix and match” dose

The U.S. Food and Drug Administration (FDA) on Wednesday authorized COVID-19 booster doses of Moderna and Johnson & Johnson, and approved “mix and match” booster dose for currently available approved COVID-19 vaccines.

The agency authorized the use of a single booster dose of the Moderna COVID-19 vaccine at least 6 months after completion of the primary shots to people 65 years of age and older, 18 through 64 years of age at high risk of severe COVID-19, and 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2.

As for the Johnson & Johnson booster dose, the FDA authorized the use of a single booster dose at least 2 months after completion of the single-dose primary regimen to individuals 18 years of age and older.

A single booster dose of any of the available COVID-19 vaccines may be administered as a “mix and match” booster dose following completion of primary vaccination with a different available COVID-19 vaccine, according to the FDA.

For instance, a person who got a Johnson & Johnson vaccine could receive one from Moderna or Pfizer-BioNTech as a booster.

“The available data suggest waning immunity in some populations who are fully vaccinated,” said Acting FDA Commissioner Janet Woodcock in a statement. “The availability of these authorized boosters is important for continued protection against COVID-19 disease.”

The decision came after an FDA advisory committee voted last week to recommend authorizing Moderna and Johnson & Johnson’s COVID-19 booster doses.

In September, the FDA authorized the first booster shots for the Pfizer-BioNTech COVID-19 vaccine, allowing a single booster dose of the Pfizer-BioNTech vaccine be administered at least 6 months after completion of the primary series to individuals 65 years of age and older, and 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2.

A recent study of the “mix and match” approach funded by the U.S. National Institutes of Health found no safety concerns using different vaccines as a booster.

The study found that people who received the Johnson & Johnson vaccine produced stronger antibody levels after they got booster shots made by Moderna or Pfizer-BioNTech, compared to boosters from Johnson & Johnson. -rir

Popular

Palace: No holiday break for PBBM, key agencies during Holy Week

By Ruth Abbey Gita-Carlos | Philippine News Agency There will be no holiday break for President Ferdinand R. Marcos Jr. and key government agencies during...

PBBM: 131 Kalayaan Island features in Palawan, WPS to adopt local names

By Dean Aubrey Caratiquet In a move to assert sovereignty over the hotly contested islands and features in the West Philippine Sea (WPS), President Ferdinand...

DBCC to discuss oil excise tax this week —PBBM

By Brian Campued The Development Budget Coordination Committee (DBCC) is set to convene this week to discuss its assessment on the possible implementation of a...

Malacañang sets half-day WFH setup for gov’t offices on Holy Wednesday

By Brian Campued Malacañang on Tuesday directed government offices to implement work-from-home arrangement on Holy Wednesday, in light of the observance of Holy Week. In Memorandum...